Aretaeus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 30-07-2024
- Paid Up Capital ₹ 7.50 M
as on 30-07-2024
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.22 Cr
as on 30-07-2024
- Revenue -5.24%
(FY 2023)
- Profit -29.73%
(FY 2023)
- Ebitda 5.43%
(FY 2023)
- Net Worth 4.49%
(FY 2023)
- Total Assets 7.79%
(FY 2023)
About Aretaeus Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹2.22 Cr.
Ravinder Thupaikula, Periyasamy Sivaranjan, Gowri Ravinder, and One other member serve as directors at the Company.
- CIN/LLPIN
U36912TN2009PTC071309
- Company No.
071309
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Apr 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aretaeus Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravinder Thupaikula  | Director | 15-Apr-2009 | Current |
| Periyasamy Sivaranjan | Director | 15-Apr-2009 | Current |
| Gowri Ravinder | Director | 15-Apr-2009 | Current |
| Santhi Subramaniam | Director | 15-Apr-2009 | Current |
Financial Performance of Aretaeus Pharmaceuticals.
Aretaeus Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.24% decrease. The company also saw a substantial fall in profitability, with a 29.73% decrease in profit. The company's net worth moved up by a moderate rise of 4.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aretaeus Pharmaceuticals?
In 2023, Aretaeus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Oct 2009 | ₹2.22 Cr | Open |
How Many Employees Work at Aretaeus Pharmaceuticals?
Aretaeus Pharmaceuticals has a workforce of 49 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aretaeus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aretaeus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
